AMRX
Amneal Pharmaceuticals, Inc.
AMRX's fundamentals are strong: earnings per share grew more than tenfold and its operating margin rose 3 points to 15%, though free cash flow fell 67%. At 53x earnings, it's trading in line with its usual 58x. Analysts expect that strong growth to continue.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AMRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Unavailable |
AMRX's revenue and profitability are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AMRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $5.39 | -75% |
| Forward | 19x | $21.70 | — |
| Current | 53x | $21.70 | — |
| Fair | 58x | $23.71 | +9.2% |
| Expensive | 616x | $253 | +1064% |
Historical ranges are pointers, not guarantees.
AMRX's PE is in its fair range at 53x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AMRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
AMRX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.14 | +178% |
| Q3 2026 | $0.41 | +1950% |
| Q2 2026 | $0.48 | +4700% |
| Q1 2026 | $0.37 | +$0.41 |
| Q4 2025 | $0.22 | +$0.60 |
| Q3 2025 | $0.02 | +$0.87 |
| Q2 2025 | $0.01 | +$0.80 |
| Q1 2025 | -$0.04 | +$0.69 |
| Q4 2024 | -$0.38 | +$0.10 |
AMRX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11% |
| Q3 2025 | $784.5M | +12% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18% |
AMRX's revenue has grown year over year for 22 quarters in a row: $863M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +2.1 points |
| Q2 2026 | 16% | +0.9 points |
| Q1 2026 | 20% | +5.2 points |
| Q4 2025 | 14% | +3.4 points |
| Q3 2025 | 9% | -3.7 points |
| Q2 2025 | 15% | +1.8 points |
| Q1 2025 | 14% | +16 points |
| Q4 2024 | 10% | +8.1 points |
AMRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AMRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $66.5M | -37% |
| Q2 2026 | -$51.9M | -185% |
| Q1 2026 | -$34.9M | -$29.2M |
| Q4 2025 | $108.5M | +5.5% |
| Q3 2025 | $106.2M | -15% |
| Q2 2025 | $61M | +110% |
| Q1 2025 | -$5.8M | +$7.9M |
| Q4 2024 | $102.9M | -18% |
AMRX still generates free cash flow, though less than at its 2020 peak: $88M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AMRX on cash flow, with more consistent year-over-year improvement.
AMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +7.6M shares |
| 1 year | +3.4% | +11M shares |
| 3 years | +117% | +181M shares |
| 5 years | +121% | +184M shares |
| Available history | +154% | +204M shares |
AMRX has 336M diluted shares, up 3.4% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AMRX Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 86.7 | Overbought |
AMRX's weekly RSI is 69 (neutral) and its Stochastic is 87 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AMRX PE vs Healthcare Sector
| Metric | AMRX | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 105% above |
| PE % | 40 | 29 | 11 pts above |
AMRX is trading at 53x earnings, a 105% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 6.6% above |
| 20 week MA | $18.8 | 15% above |
| 50 week MA | $15.5 | 40% above |
| 100 week MA | $12.1 | 79% above |
| 200 week MA | $8.62 | 152% above |
AMRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.51 | $4.43 | -1.8% |
| 2021 | $4.43 | $5.07 | +14% |
| 2022 | $5.07 | $2.20 | -57% |
| 2023 | $2.20 | $6.07 | +176% |
| 2024 | $6.07 | $7.82 | +29% |
| 2025 | $7.82 | $13.0 | +66% |
| 2026 YTD | $13.0 | $21.7 | +68% |
AMRX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.